

# Stefania Merighi

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7583000/stefania-merighi-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

119  
papers

6,318  
citations

46  
h-index

77  
g-index

127  
ext. papers

7,225  
ext. citations

6.5  
avg, IF

5.48  
L-index

#	Paper	IF	Citations
119	A glance at adenosine receptors: novel target for antitumor therapy <b>2003</b> , 100, 31-48		373
118	A(3) adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study. <i>Molecular Pharmacology</i> , <b>2002</b> , 61, 415-24	4.3	317
117	Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. <i>Journal of Medicinal Chemistry</i> , <b>2004</b> , 47, 1434-47	8.3	298
116	Pharmacology of Adenosine Receptors: The State of the Art. <i>Physiological Reviews</i> , <b>2018</b> , 98, 1591-1625	47.9	259
115	Pyrazolotriazolopyrimidine derivatives sensitize melanoma cells to the chemotherapeutic drugs: taxol and vindesine. <i>Biochemical Pharmacology</i> , <b>2003</b> , 66, 739-48	6	227
114	The A3 adenosine receptor: an enigmatic player in cell biology <b>2008</b> , 117, 123-40		177
113	Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects?. <i>Trends in Pharmacological Sciences</i> , <b>2016</b> , 37, 419-434	13.2	174
112	The A3 adenosine receptor: history and perspectives. <i>Pharmacological Reviews</i> , <b>2015</b> , 67, 74-102	22.5	162
111	Adenosine receptors and cancer. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , <b>2011</b> , 1808, 1400-12	3.8	158
110	Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. <i>Molecular Pharmacology</i> , <b>2007</b> , 72, 395-406	4.3	136
109	A(2A) adenosine receptors in human peripheral blood cells. <i>British Journal of Pharmacology</i> , <b>2000</b> , 129, 2-11	8.6	124
108	A(3) adenosine receptor ligands: history and perspectives. <i>Medicinal Research Reviews</i> , <b>2000</b> , 20, 103-28	14.4	117
107	Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. <i>Journal of Investigative Dermatology</i> , <b>2002</b> , 119, 923-33	4.3	115
106	Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells. <i>Biochemical Pharmacology</i> , <b>2006</b> , 72, 19-31	6	106
105	Effect of low frequency electromagnetic fields on A2A adenosine receptors in human neutrophils. <i>British Journal of Pharmacology</i> , <b>2002</b> , 136, 57-66	8.6	100
104	Characterization of adenosine receptors in bovine chondrocytes and fibroblast-like synoviocytes exposed to low frequency low energy pulsed electromagnetic fields. <i>Osteoarthritis and Cartilage</i> , <b>2008</b> , 16, 292-304	6.2	98
103	A3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 19516-26	5.4	98

102	Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A(3) adenosine subtype. <i>Journal of Cellular Physiology</i> , <b>2007</b> , 211, 826-36	7	96
101	Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. <i>British Journal of Pharmacology</i> , <b>2001</b> , 134, 1215-26	8.6	93
100	Dose and time effects of caffeine intake on human platelet adenosine A(2A) receptors : functional and biochemical aspects. <i>Circulation</i> , <b>2000</b> , 102, 285-9	16.7	92
99	Caffeine alters A2A adenosine receptors and their function in human platelets. <i>Circulation</i> , <b>1999</b> , 99, 2499-502	16.7	89
98	Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells. <i>British Journal of Pharmacology</i> , <b>2001</b> , 134, 116-26	8.6	88
97	Pulsed electromagnetic fields increased the anti-inflammatory effect of A <sub>2A</sub> and A <sub>2B</sub> adenosine receptors in human T/C-28a2 chondrocytes and hFOB 1.19 osteoblasts. <i>PLoS ONE</i> , <b>2013</b> , 8, e65561	3.7	84
96	A Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy. <i>Medicinal Research Reviews</i> , <b>2018</b> , 38, 1031-1072	14.4	82
95	Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists: influence of the chain at the N(8) pyrazole nitrogen. <i>Journal of Medicinal Chemistry</i> , <b>2000</b> , 43, 4768-80	8.3	82
94	Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists. <i>Journal of Medicinal Chemistry</i> , <b>1999</b> , 42, 4473-8	8.3	75
93	Expression of A3 adenosine receptors in human lymphocytes: up-regulation in T cell activation. <i>Molecular Pharmacology</i> , <b>2004</b> , 65, 711-9	4.3	72
92	Morphine mediates a proinflammatory phenotype via $\mu$ opioid receptor-PKC $\epsilon$ -Akt-ERK1/2 signaling pathway in activated microglial cells. <i>Biochemical Pharmacology</i> , <b>2013</b> , 86, 487-96	6	70
91	Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells. <i>Molecular Pharmacology</i> , <b>2007</b> , 72, 162-72	4.3	70
90	A3 adenosine receptors modulate hypoxia-inducible factor-1 $\alpha$ expression in human A375 melanoma cells. <i>Neoplasia</i> , <b>2005</b> , 7, 894-903	6.4	70
89	Adenosine modulates HIF-1 $\alpha$ , VEGF, IL-8, and foam cell formation in a human model of hypoxic foam cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2010</b> , 30, 90-7	9.4	65
88	Temporal mapping of transcripts in herpesvirus 6 variants. <i>Journal of Virology</i> , <b>1998</b> , 72, 3837-44	6.6	65
87	Pathological overproduction: the bad side of adenosine. <i>British Journal of Pharmacology</i> , <b>2017</b> , 174, 1945-1960	5.6	64
86	Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists. <i>Journal of Medicinal Chemistry</i> , <b>2003</b> , 46, 1229-41	8.3	63
85	Adenosine receptor targeting in health and disease. <i>Expert Opinion on Investigational Drugs</i> , <b>2011</b> , 20, 1591-609	5.9	62

84	Adenosine and lymphocyte regulation. <i>Purinergic Signalling</i> , <b>2007</b> , 3, 109-16	3.8	62
83	Adenosine receptors in health and disease. <i>Advances in Pharmacology</i> , <b>2011</b> , 61, 41-75	5.7	59
82	A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. <i>Neoplasia</i> , <b>2009</b> , 11, 1064-74	6.4	59
81	Expression, pharmacological profile, and functional coupling of A2B receptors in a recombinant system and in peripheral blood cells using a novel selective antagonist radioligand, [ <sup>3</sup> H]MRE 2029-F20. <i>Molecular Pharmacology</i> , <b>2005</b> , 67, 2137-47	4.3	58
80	Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors. <i>Biochemical Pharmacology</i> , <b>2010</b> , 79, 1483-95	6	57
79	Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. <i>Biochemical Pharmacology</i> , <b>2005</b> , 70, 1601-12	6	51
78	The activation of $\mu$ -opioid receptor potentiates LPS-induced NF- $\kappa$ B promoting an inflammatory phenotype in microglia. <i>FEBS Letters</i> , <b>2016</b> , 590, 2813-26	3.8	49
77	Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain models. <i>Pain</i> , <b>2013</b> , 154, 864-73	8	49
76	Medicinal Chemistry, Pharmacology, and Clinical Implications of TRPV1 Receptor Antagonists. <i>Medicinal Research Reviews</i> , <b>2017</b> , 37, 936-983	14.4	47
75	The Role of Adenosine Receptors in Psychostimulant Addiction. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 985	5.6	46
74	TRR469, a potent A(1) adenosine receptor allosteric modulator, exhibits anti-nociceptive properties in acute and neuropathic pain models in mice. <i>Neuropharmacology</i> , <b>2014</b> , 81, 6-14	5.5	46
73	Cannabinoid CB(2) receptor attenuates morphine-induced inflammatory responses in activated microglial cells. <i>British Journal of Pharmacology</i> , <b>2012</b> , 166, 2371-85	8.6	46
72	Synthesis and biological effects of novel 2-amino-3-naphtho[1,2-b]thiophenes as allosteric enhancers of the A1 adenosine receptor. <i>Journal of Medicinal Chemistry</i> , <b>2003</b> , 46, 794-809	8.3	44
71	A adenosine receptors stimulate IL-6 production in primary murine microglia through p38 MAPK kinase pathway. <i>Pharmacological Research</i> , <b>2017</b> , 117, 9-19	10.2	42
70	New pyrrolo[2,1-f]purine-2,4-dione and imidazo[2,1-f]purine-2,4-dione derivatives as potent and selective human A3 adenosine receptor antagonists. <i>Journal of Medicinal Chemistry</i> , <b>2005</b> , 48, 4697-701	8.3	40
69	Adenosine Receptors as a Biological Pathway for the Anti-Inflammatory and Beneficial Effects of Low Frequency Low Energy Pulsed Electromagnetic Fields. <i>Mediators of Inflammation</i> , <b>2017</b> , 2017, 2740963	4.3	39
68	A(1) and A(3) adenosine receptors inhibit LPS-induced hypoxia-inducible factor-1 accumulation in murine astrocytes. <i>Pharmacological Research</i> , <b>2013</b> , 76, 157-70	10.2	39
67	Cannabinoid CB(2) receptors modulate ERK-1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide. <i>British Journal of Pharmacology</i> , <b>2012</b> , 165, 1773-1788	8.6	39

66	Role and Function of A and A <sub>2A</sub> Adenosine Receptors in Patients with Ankylosing Spondylitis, Psoriatic Arthritis and Rheumatoid Arthritis. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	38
65	Multiple sclerosis lymphocytes upregulate A <sub>2A</sub> adenosine receptors that are antiinflammatory when stimulated. <i>European Journal of Immunology</i> , <b>2013</b> , 43, 2206-16	6.1	37
64	A <sub>2A</sub> adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats. <i>PLoS ONE</i> , <b>2013</b> , 8, e54195	3.7	37
63	Allosteric enhancers of A <sub>1</sub> adenosine receptors: state of the art and new horizons for drug development. <i>Current Medicinal Chemistry</i> , <b>2010</b> , 17, 3488-502	4.3	37
62	Nociceptin receptor binding in mouse forebrain membranes: thermodynamic characteristics and structure activity relationships. <i>British Journal of Pharmacology</i> , <b>1998</b> , 125, 1485-90	8.6	35
61	[ <sup>3</sup> H]-MRE 2029-F20, a selective antagonist radioligand for the human A <sub>2B</sub> adenosine receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2004</b> , 14, 3607-10	2.9	34
60	A <sub>1</sub> and A <sub>2A</sub> adenosine receptors affect HIF-1 $\beta$ signaling in activated primary microglial cells. <i>Glia</i> , <b>2015</b> , 63, 1933-1952	9	33
59	Pulsed Electromagnetic Field Exposure Reduces Hypoxia and Inflammation Damage in Neuron-Like and Microglial Cells. <i>Journal of Cellular Physiology</i> , <b>2017</b> , 232, 1200-1208	7	32
58	Inhibition of A <sub>2A</sub> Adenosine Receptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 888	5.6	32
57	Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine ligands, new tools to characterize A <sub>3</sub> adenosine receptors in human tumor cell lines. <i>Current Medicinal Chemistry</i> , <b>2005</b> , 12, 1319-29	4.3	32
56	Biochemical and Pharmacological Role of A <sub>2A</sub> Adenosine Receptors and Their Modulation as Novel Therapeutic Strategy. <i>Advances in Experimental Medicine and Biology</i> , <b>2017</b> , 1051, 193-232	3.6	31
55	Hydrogen sulfide modulates the release of nitric oxide and VEGF in human keratinocytes. <i>Pharmacological Research</i> , <b>2012</b> , 66, 428-36	10.2	31
54	The anti-tumor effect of A <sub>3</sub> adenosine receptors is potentiated by pulsed electromagnetic fields in cultured neural cancer cells. <i>PLoS ONE</i> , <b>2012</b> , 7, e39317	3.7	31
53	Pharmacological characterization of P2X <sub>1</sub> and P2X <sub>3</sub> purinergic receptors in bovine chondrocytes. <i>Osteoarthritis and Cartilage</i> , <b>2008</b> , 16, 1421-9	6.2	31
52	Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A <sub>2A</sub> adenosine receptor. <i>Purinergic Signalling</i> , <b>2006</b> , 2, 627-32	3.8	30
51	Synthesis and activity of 3-pyridylamine ligands at central nicotinic receptors. <i>European Journal of Medicinal Chemistry</i> , <b>2000</b> , 35, 979-88	6.8	29
50	Adenosine receptors and diabetes: Focus on the A <sub>2B</sub> adenosine receptor subtype. <i>Pharmacological Research</i> , <b>2015</b> , 99, 229-36	10.2	27
49	Recent developments in the field of A <sub>3</sub> adenosine receptor antagonists. <i>Drug Development Research</i> , <b>2003</b> , 58, 315-329	5.1	27

48	Alteration of A(3) adenosine receptors in human neutrophils and low frequency electromagnetic fields. <i>Biochemical Pharmacology</i> , <b>2003</b> , 66, 1897-906	6	26
47	Glucocorticoids pharmacology: past, present and future. <i>Current Pharmaceutical Design</i> , <b>2010</b> , 16, 3540-53	5.3	25
46	Binding thermodynamics at the human A(3) adenosine receptor. <i>Biochemical Pharmacology</i> , <b>2002</b> , 63, 157-61	6	25
45	Positive allosteric modulation of A adenosine receptors as a novel and promising therapeutic strategy for anxiety. <i>Neuropharmacology</i> , <b>2016</b> , 111, 283-292	5.5	24
44	Binding thermodynamics at the human cannabinoid CB1 and CB2 receptors. <i>Biochemical Pharmacology</i> , <b>2010</b> , 79, 471-7	6	20
43	Receptor binding thermodynamics at the neuronal nicotinic receptor. <i>Current Topics in Medicinal Chemistry</i> , <b>2004</b> , 4, 361-8	3	20
42	Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor ligands: A starting point for searching A2B adenosine receptor antagonists. <i>Drug Development Research</i> , <b>2001</b> , 53, 225-235	5.1	19
41	Pulsed electromagnetic field and relief of hypoxia-induced neuronal cell death: The signaling pathway. <i>Journal of Cellular Physiology</i> , <b>2019</b> , 234, 15089	7	19
40	Synthesis and preliminary biological evaluation of [3H]-MRE 3008-F20: the first high affinity radioligand antagonist for the human A3 adenosine receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2000</b> , 10, 209-11	2.9	18
39	Thermodynamics of A2B adenosine receptor binding discriminates agonistic from antagonistic behaviour. <i>Biochemical Pharmacology</i> , <b>2008</b> , 75, 562-9	6	17
38	Targeting A3 and A2A adenosine receptors in the fight against cancer. <i>Expert Opinion on Therapeutic Targets</i> , <b>2019</b> , 23, 669-678	6.4	16
37	PKC $\delta$ is a novel promoter of skeletal muscle differentiation and regeneration. <i>Experimental Cell Research</i> , <b>2015</b> , 339, 10-9	4.2	14
36	Effects of two-carbon bridge region methoxylation of benztropine: discovery of novel chiral ligands for the dopamine transporter. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2001</b> , 11, 823-7	2.9	14
35	Synthesis, molecular modeling and SAR study of novel pyrazolo[5,1-f][1,6]naphthyridines as CB receptor antagonists/inverse agonists. <i>Bioorganic and Medicinal Chemistry</i> , <b>2016</b> , 24, 5291-5301	3.4	12
34	Water-soluble pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. <i>Journal of Medicinal Chemistry</i> , <b>2012</b> , 55, 5380-90	8.3	10
33	Adenosine receptors and human melanoma. <i>Drug Development Research</i> , <b>2003</b> , 58, 377-385	5.1	10
32	Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: A new pharmacological tool for the characterization of the human A3 adenosine receptor. <i>Drug Development Research</i> , <b>2001</b> , 52, 406-415	5.1	10
31	Adenosine Receptors: Structure, Distribution, and Signal Transduction <b>2018</b> , 33-57		9

30	Downregulation of A(1) and A(2B) adenosine receptors in human trisomy 21 mesenchymal cells from first-trimester chorionic villi. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2012</b> , 1822, 1660-70	6.9	9
29	Binding thermodynamic characterization of human P2X1 and P2X3 purinergic receptors. <i>Biochemical Pharmacology</i> , <b>2008</b> , 75, 1198-208	6	9
28	Synthesis and pharmacology of 6-substituted benzotropines: discovery of novel dopamine uptake inhibitors possessing low binding affinity to the dopamine transporter. <i>Journal of Medicinal Chemistry</i> , <b>2005</b> , 48, 3337-43	8.3	8
27	An Open Question: Is the A Adenosine Receptor a Novel Target for Alzheimer's Disease Treatment?. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 652455	5.6	8
26	Deregulation of Adenosine Receptors in Psoriatic Epidermis: An Option for Therapeutic Treatment. <i>Journal of Investigative Dermatology</i> , <b>2017</b> , 137, 11-13	4.3	7
25	Targeting adenosine receptors to prevent inflammatory skin diseases. <i>Experimental Dermatology</i> , <b>2014</b> , 23, 553-4	4	7
24	Cytokine Profiling in Myeloproliferative Neoplasms: Overview on Phenotype Correlation, Outcome Prediction, and Role of Genetic Variants. <i>Cells</i> , <b>2020</b> , 9,	7.9	7
23	Upregulation of Cortical A2A Adenosine Receptors Is Reflected in Platelets of Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2021</b> , 80, 1105-1117	4.3	7
22	The Detrimental Action of Adenosine on Glutamate-Induced Cytotoxicity in PC12 Cells Can Be Shifted towards a Neuroprotective Role through AAR Positive Allosteric Modulation. <i>Cells</i> , <b>2020</b> , 9,	7.9	6
21	Novel selective antagonist radioligands for the pharmacological study of A(2B) adenosine receptors. <i>Purinergic Signalling</i> , <b>2006</b> , 2, 583-8	3.8	6
20	Synthesis and Biological Evaluation of Pyrazolo[3,4-b]pyridin-4-ones as a New Class of Topoisomerase II Inhibitors. <i>Medicinal Chemistry</i> , <b>2015</b> , 11, 342-53	1.8	6
19	Signaling pathways involved in anti-inflammatory effects of Pulsed Electromagnetic Field in microglial cells. <i>Cytokine</i> , <b>2020</b> , 125, 154777	4	6
18	Adenosine Receptors and Current Opportunities to Treat Cancer <b>2018</b> , 543-555		5
17	Synthesis and biological activity of a novel class nicotinic acetylcholine receptors (nAChRs) ligands structurally related to anatoxin-a. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2011</b> , 21, 5423-7	2.9	4
16	Adenosine A2A receptors of human circulating blood elements. <i>Drug Development Research</i> , <b>1998</b> , 45, 253-260	5.1	4
15	Synthesis and Biological Evaluation of Allosteric A1-Adenosine Receptor Modulators Structurally Related to (2-Amino-4,5,6,7-Tetrahydro-Benzo[B]Thiophen-3-yl)-(4-Chloro-Phenyl)-Methanone, a Potent Compound Useful to Reduce Neuropathic Pain. <i>Medicinal Chemistry Research</i> , <b>2005</b> , 14, 125-142	2.2	4
14	Regulation of Second Messenger Systems and Intracellular Pathways <b>2010</b> , 61-73		4
13	Alzheimer and Purinergic Signaling: Just a Matter of Inflammation?. <i>Cells</i> , <b>2021</b> , 10,	7.9	4

12	Antioxidant and Antiinflammatory Effects of , and Plant Extracts in Macrophage and Microglial Cells. <i>Cells</i> , <b>2021</b> , 10,	7.9	3
11	A Adenosine Receptor as a Potential Biomarker and a Possible Therapeutic Target in Alzheimer's Disease. <i>Cells</i> , <b>2021</b> , 10,	7.9	3
10	van Hoff Based Thermodynamics. <i>Methods and Principles in Medicinal Chemistry</i> , <b>2015</b> , 15-35	0.4	2
9	Adenosine Receptors in Neuropsychiatric Disorders: Fine Regulators of Neurotransmission and Potential Therapeutic Targets.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	2
8	Agonists and Antagonists: Molecular Mechanisms and Therapeutic Applications <b>2010</b> , 301-317		2
7	A Adenosine Receptor Partial Agonists and Allosteric Modulators: Advancing Toward the Clinic?. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 625134	5.6	2
6	Adenosinergic System Involvement in Ischemic Stroke Patients Lymphocytes. <i>Cells</i> , <b>2020</b> , 9,	7.9	1
5	Synthesis, Pharmacological Evaluation, and Docking Studies of Novel Pyridazinone-Based Cannabinoid Receptor Type 2 Ligands. <i>ChemMedChem</i> , <b>2018</b> , 13, 1102-1114	3.7	1
4	Adenosine Receptors: The Status of the Art <b>2018</b> , 1-11		1
3	Thermodynamic Analysis in Drug Receptor Binding: The A3 Adenosine Receptor <b>2010</b> , 29-48		
2	Synthesis and binding of 3-aminopyridine derivatives at central nicotinic receptors. <i>Arzneimittelforschung</i> , <b>2000</b> , 50, 507-11		
1	Synthesis, biological evaluation and docking studies of a novel class of sulfur-bridged diazabicyclo[3.3.1]nonanes. <i>Bioorganic Chemistry</i> , <b>2020</b> , 102, 104072	5.1	